Showing 5431-5440 of 6808 results for "".
- New Studies Support Taltz’s Role in Treating Psoriasishttps://practicaldermatology.com/news/new-studies-support-taltzs-role-in-treating-psoriasis/2460771/Lilly's Taltz delivers more cumulative days with completely clear skin for adults with psoriasis, compared to seven other biologics. What’s more, Taltz also helped patients stay on treatment longer and have more days without additional therapy in three real-world analyses of U
- Roflumilast Foam and Cream Show Promise in Multiple Skin Diseaseshttps://practicaldermatology.com/news/roflumilast-foam-and-cream-show-promise-in-multiple-skin-diseases/2460767/Roflumilast foam significantly improved both scalp and body psoriasis, with improvement as early as two weeks after treatment initiation, data presented at the 2021 AAD VMX show. Additionally, data presented in posters at the AAD VMX show that roflumilast foam is a safe, well-tolerated, and effec
- Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitishttps://practicaldermatology.com/news/etrasimod-performs-well-in-phase-phase-2b-trial-of-adult-atopic-dermatitis/2460761/Arena Pharmaceuticals, Inc.’s Etrasimod demonstrated statistical significance in both clinician and patient reported outcomes in atopic dermatitis, according to research presented at the American Academy of Dermatology VMX Experience. Etrasimod is an investigational, highly select
- C-Jun Protein May Play Role in Psoriasis Developmenthttps://practicaldermatology.com/news/c-jun-protein-may-play-role-in-psoriasis-development/2460753/The "c-Jun" protein may play a major role in the development of psoriasis, but inhibiting this protein may alleviate symptoms, new research suggests. c-Jun belongs to a larger family of transcription factors, DNA-binding factors, known as Activator Protein-1 (AP-1). Previ
- Kintor Doses First Group of Acne Patients in Phase I/II Clinical Trial of Pyrilutamidehttps://practicaldermatology.com/news/kintor-doses-first-group-of-acne-patients-in-phase-iii-clinical-trial-of-pyrilutamide/2460752/Kintor Pharmaceutical Limited successfully dosed the first group of patients in the clinical trial of Pyrilutamide as a treatment for the acne vulgaris. The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evalu
- First Launch from FlawlessCanvas Now Availablehttps://practicaldermatology.com/news/first-launch-from-flawlesscanvas-now-available/2460750/Quantum Lift Reset Serum™ is now available from FlawlessCanvas, Inc., direct to its Facebook and Instagram followers. “The design of FlawlessCanvas Quantum Lift Reset Serum™ was based on
- DecisionDx-Melanoma Accurately Predicts Patient Outcomes in Cutaneous Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-accurately-predicts-patient-outcomes-in-cutaneous-melanoma/2460746/Castle Biosciences, Inc.’s DecisionDx-Melanoma is a significant, independent predictor of patient outcomes in cutaneous melanoma. DecisionDx-Melanoma is Castle’s gene expression profile test that uses an individual patient’s tumor biology to predict risk of cutane
- Industry Optimism Surges: Three Ways for Dermatologists to Capitalizehttps://practicaldermatology.com/news/industry-optimism-surges-three-way-for-dermatologists-to-capitalize/2460745/Despite a tumultuous past year, a recent Medscape survey shows that 85 percent of dermatologists are happy with their profession and optimistic about the future. This optimism is likely brought on by
- Thiazide Diuretics Linked to Skin Cancer Riskhttps://practicaldermatology.com/news/thiazide-diuretics-linked-to-skin-cancer-risk/2460744/Use of certain blood pressure-lowering medications may increase risk for skin cancer, a new study shows. Researchers reviewed data for nearly 303,000 adults in Ontario over age 65 who were prescribed medications for high bl
- Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream for Pediatric ADhttps://practicaldermatology.com/news/arcutis-initiates-phase-3-clinical-trial-of-topical-roflumilast-cream-for-pediatric-ad/2460743/Arcutis Biotherapeutics, Inc. initiated a pivotal Phase 3 clinical trial evaluating topical roflumilast cream (ARQ-151) as a potential treatment for mild to moderate atopic dermatitis (AD) in patients between the ages of 2 and 5 years old. Roflumilast cream is a once daily topical formulation of